ArticleJournal of Crohn's & colitis2021
Gut microbiota-driven drug metabolism in inflammatory bowel disease.
Article in Journal of Crohn's & colitis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review.Journal of Crohn's & colitis · 2022Pooled it
- Effect of curcumin on the gut microbiota of patients with ulcerative colitis, Crohn's disease and healthy participants.Scientific reports · 2026Trial
- Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy.Gut microbes · 2026Review
- Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.Alimentary pharmacology & therapeutics · 2026Review
- Ingestible probes for breath-based monitoring of drug-metabolizing activity from the microbiome.Science advances · 2026Article
- Probiotics unveiled: bridging general health benefits to the era of precision medicine.World journal of microbiology & biotechnology · 2026Review
- Emerging Role of Gut Microbiota in Modulating Response to Therapies in IBD.Microorganisms · 2026Review
- Enzyme-Responsive Polymeric Drug Delivery Systems for the Treatment of Inflammatory Bowel Diseases: A Review.Polymers · 2026Review
- Microbiota-based PBPK model: new approach methodology for assessing the kinetics of drugs and chemicals.Frontiers in pharmacology · 2026Review
- Microbiome-aware oral drug delivery: excipient-microbiome interactions and nanocarrier design rules for predictable formulation performance.Frontiers in pharmacology · 2026Review
- Antibiotics administration during weaning ameliorates intestinal mucosal inflammation in adult mice and their offspring.Frontiers in immunology · 2026Article
- An overview of the role of the gut microbiota in rheumatoid arthritis.Microbiome research reports · 2026Review
- The oral‒gut axis in periodontal disease: a systematic review of the associated human evidence of its mechanisms and implications for patient care.Journal of oral microbiology · 2026Review
- Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Gut bacteria-derived metabolites and their implications in mental health and neurological diseases.World journal of microbiology & biotechnology · 2025Review
- Gut bacteria and the host synergies promote resveratrol metabolism and induce tolerance in ALD mice.NPJ biofilms and microbiomes · 2025Article
- Gut Microbiota Disruption in Hematologic Cancer Therapy: Molecular Insights and Implications for Treatment Efficacy.International journal of molecular sciences · 2024Review
- Article
- Pulchinenoside B4 ameliorates oral ulcers in rats by modulating gut microbiota and metabolites.Applied microbiology and biotechnology · 2024Article
- Novel Techniques and Models for Studying the Role of the Gut Microbiota in Drug Metabolism.European journal of drug metabolism and pharmacokinetics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe gut microbiota plays an important role in the metabolization and modulation of several types of drugs. With this study we aimed to review the literature about microbial drug metabolism of medication prescribed in inflammatory bowel disease practice.
methodsA systematic literature search was performed in Embase and PubMed from inception to October 2019. The search was conducted with predefined MeSH/Emtree and text terms. All studies about drug metabolism by microbiota of medication prescribed in inflammatory bowel disease practice were eligible. A total of 1018 records were encountered and 89 articles were selected for full text reading.
resultsIntestinal bacterial metabolism or modulation is of influence in four specific drugs used in inflammatory bowel disease (mesalazines, methotrexate, glucocorticoids and thioguanine). The gut microbiota cleaves the azo-bond of sulfasalazine, balsalazide and olsalazine and releases the active moiety 5-aminosalicylic acid. It has an impact on the metabolization and potentially on the response of methotrexate therapy. Especially thioguanine can be converted by intestinal bacteria into the pharmacological active 6-thioguanine nucleotides without the requirement of host metabolism. Glucocorticoid compounds can be prone to bacterial degradation.
conclusionThe human intestinal microbiota can have a major impact on drug metabolism and efficacy of medication prescribed in inflammatory bowel disease practice. A better understanding of these interactions between microbiota and drugs is needed and should be an integral part of the drug development pathway of new inflammatory bowel disease medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.